Relmada Therapeutics, Inc.
We are a late-stage biotech company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Our most advanced program is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels associated with major depressive disorder (MDD), while maintaining physiological glutamatergic neurotransmission. We believe that REL-1017 has the potential to transform the current neuropharmacological approach to MDD, and we are rapidly advancing toward investigating REL-1017 for potential indications as adjunctive and monotherapy.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Globally (various continents)
About Us
Depression represents the largest cause of disability around the world1. Our dedicated team is focused on moving REL-1017 forward as a potentially transformational option for people living with MDD.
Based on our Phase 1 and Phase 2 studies, we believe there is a real potential for REL-1017 to treat MDD safely, effectively, and more quickly than is currently possible with a well-tolerated, oral, once-daily tablet. REL-1017 received Fast Track Designation and has entered the pivotal Phase 3 programs with studies as an adjunctive treatment in adults. REL-1017 has also initiated a Phase 3 study for monotherapy.
We are growing our company accordingly as we execute our Phase 3 program: Reliance I, Reliance II, Reliance III, and Reliance-OLS for REL-1017. We have assembled an experienced development team to advance this promising program.
Our Clinical Focus
Given the significant need and our innovative research, we are focused on diseases of the central nervous system (CNS).
There is a major need for additional treatments for major depressive disorder.
According to the World Health Organization (WHO), depression is the leading cause of ill health and disability worldwide. According to WHO’s latest estimates, more than 300 million people are now living with depression, an increase of more than 18% between 2005 and 2015. As many as 65 million Americans will experience at least one episode of depression in their lifetime.
Despite multiple drug classes and dozens of approved therapies, additional safe, effective, and well-tolerated options are still needed to successfully treat major depressive disorder (MDD).
Delayed onset of action, side effects and poor tolerability limit effectiveness of many current treatment options.
Challenges with delayed onset of action, side effects and tolerability also limit treatment effectiveness by contributing to non-adherence and/or treatment discontinuation.